Gossamer Bio Inc 2025年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedSeptember30, 2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from ________to_________.Commission File Number:001-38796_________________________ GOSSAMER BIO, INC. (Exact name of Registrant as specified in its charter)._________________________ 47-5461709(I.R.S. EmployerIdentification No.) Registrant’s telephone number, including area code: (858)684-1300 Securities registered pursuant to Section 12(b) of the Act: TradingSymbol(s) Name of each exchange on which registered Nasdaq Global Select Market Indicate by check mark whether the Registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports),and (2)has been subject to such filing requirements for the past 90 days:Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theRegistrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Table of Contents Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YES☐NO☒As of October31, 2025, the registrant had231,456,247shares of common stock ($0.0001 par value) outstanding. TABLE OF CONTENTS PART I. FINANCIAL INFORMATION Item1Condensed Consolidated Financial Statements (unaudited)Condensed Consolidated Balance Sheetsas of September30, 2025 (unaudited) and December31, 2024Condensed Consolidated Statements of Operations and ComprehensiveLossfor the Three and Nine Months endedSeptember30, 2025 and 2024 (unaudited)Condensed Consolidated Statements of Stockholders’ Equity (Deficit)for the Three and Nine Months endedSeptember30, 2025 and 2024 (unaudited)Condensed Consolidated Statements of Cash Flowsfor the Nine Months ended September30, 2025 and 2024(unaudited)Notes to Unaudited Condensed Consolidated Financial StatementsItem2Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem3Quantitative and Qualitative Disclosures About Market RiskItem4Controls and Procedures PART II. OTHER INFORMATION Item1Legal ProceedingsItem1A Risk FactorsItem2Unregistered Sales of Equity Securities and Use of ProceedsItem3Defaults Upon Senior SecuritiesItem4Mine Safety DisclosuresItem5Other InformationItem6ExhibitsExhibit IndexSignatures PART I. FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)GOSSAMER BIO, INC.Condensed Consolidated Balance Sheets(in thousands, except share and par value amounts) GOSSAMER BIO, INC.Condensed Consolidated Statements of Stockholders’ Equity (Deficit)(Unaudited)(in thousands, except share amounts) GOSSAMER BIO, INC.Condensed Consolidated Statements of Cash Flows(Unaudited)(in thousands) GOSSAMER BIO, INC.Notes to Unaudited Condensed Consolidated Financial Statements Note 1 -Description of Business Gossamer Bio, Inc. (including its subsidiaries, referred to as "we," "us," "our,", or the “Company”) is a late-stage, clinicalbiopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonaryhypertension ("PH") including pulmonary arterial hypertension ("PAH") and PH associated with interstitial lung disease ("PH-ILD").The Company was incorporated in the state of Delaware on October 25, 2015 (originally as FSG Bio, Inc.) and is based in San Diego,California. The unaudited condensed consolidated financial statements include the accounts of Gossamer Bio, Inc. and its wholly ownedsubsidiaries. All intercompany balances and transactions among the consolidated entity have been eliminated in consolidation. Liquidity and Capital Resources The Company has incurred significant operating losses since its inception. As of September30, 2025, the Company had anaccumulated deficit of $1,391.7million. From the Company’s inception through September30, 2025, the Company has funded its operations primarily through equi